Detalhe da pesquisa
1.
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial.
Cancer
; 127(5): 700-708, 2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33290610
2.
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
N Engl J Med
; 379(2): 122-137, 2018 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29863451
3.
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
Breast Cancer Res Treat
; 185(3): 697-707, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33159633
4.
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial.
Br J Cancer
; 122(10): 1453-1460, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32203207
5.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
N Engl J Med
; 377(2): 122-131, 2017 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28581356
6.
Evaluation of the effect of P-glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours.
Br J Clin Pharmacol
; 86(4): 771-778, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31770456
7.
Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.
Ann Hematol
; 98(5): 1217-1224, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30824956
8.
Adjuvant ovarian suppression in premenopausal breast cancer.
N Engl J Med
; 372(5): 436-46, 2015 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-25495490
9.
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Breast Cancer Res Treat
; 170(2): 351-360, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29589138
10.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
N Engl J Med
; 371(2): 107-18, 2014 Jul 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24881463
11.
Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial.
Ann Surg Oncol
; 24(2): 398-406, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27663567
12.
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Lancet Oncol
; 17(9): 1230-9, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27501767
13.
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
Breast Cancer Res
; 18(1): 67, 2016 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27349747
14.
Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.
Br J Cancer
; 114(2): 163-70, 2016 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26657657
15.
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
Breast Cancer Res Treat
; 158(2): 323-31, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27372069
16.
Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial.
BMC Cancer
; 16: 121, 2016 Feb 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-26887956
17.
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Lancet Oncol
; 16(1): 25-35, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25524798
18.
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
Lancet Oncol
; 15(11): 1269-78, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25273342
19.
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet Oncol
; 15(6): 580-91, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24742739
20.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
Lancet Oncol
; 15(10): 1137-46, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25130998